Drugs / Mecamylamine
Mecamylamine
also known as
ATG003 · Inversine · MEC · Mecamilamina · mecamylamine HCl · mecamylamine hydrochloride · NSC-757086
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | INVERSINE | — | 1956-03-01 | fda.gov ↗ |
Trials 16
1954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06002477 | Jun 2025 → Jun 2028 expected | subjective cognitive decline | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 0 | NCT04756232 | Apr 2022 → Apr 2025 | subjective cognitive decline | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT04129060 | Mar 2020 → Dec 2024 | Alzheimer disease | University of Vermont | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT03408574 | Oct 2016 → Dec 2021 | — | University of Vermont | Completed | No outcome recorded |
| Phase 1 | NCT00773812 | Jul 2007 → Nov 2012 | autism | Ohio State University | Completed | No outcome recorded |
| Phase 1 | NCT00018187 | Nov 1998 → Jun 2001 | — | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT00262470 | Apr 1997 → Dec 2029 expected | cardiac rhythm disease | Satish R. Raj | Active not recruiting | Missed primary |
| Phase 26 trials · 1 met primary | ||||||
| Phase 2 | NCT00607750 | May 2008 → Apr 2010 | age-related macular degeneration | CoMentis | Completed | No outcome recorded |
| Phase 2 | NCT00536692 | Sep 2007 → Apr 2008 | diabetic macular edema | CoMentis | Completed | No outcome recorded |
| Phase 2 | NCT00593879 | Feb 2005 → Aug 2006 | major depressive disorder | Targacept Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00342563 | May 2004 → Jul 2015 | alcohol dependence | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00319319 | Jan 2003 → Jan 2007 | depressive disorder | Yale University | Completed | Met primary |
| Phase 2 | NCT00018161 | Jan 1997 → Jun 2001 | — | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00563797 | Aug 2007 → Jul 2014 | alcohol dependence, major depressive disorder | Yale University | Completed | Mixed |
| Phase 41 trial | ||||||
| Phase 4 | NCT03914677 | Jun 2019 → Mar 2020 | spinal cord injury | Wayne State University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01223404 | Oct 2010 → Sep 2013 | nicotine dependence | University of Maryland, Baltimore | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00414206 Comparator | Mar 2007 → Jun 2009 | macular degeneration | CoMentis | Terminated | No outcome recorded Stop: Business |
| — | NCT00455650 Comparator | Mar 2007 → Jan 2013 | schizophrenia | Massachusetts General Hospital | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mecamylamine | “The cholinergic antagonist drug mecamylamine will be administered as a a 20 mg oral pill and matching placebo” NCT04129060 ↗ |
| Known as | ATG003 | “This is a Phase II randomized, double-masked study comparing the safety and efficacy of ATG003 (mecamylamine HCl) 1.0% and 0.3% ophthalmic solutions to placebo in patients with...” NCT00414206 ↗1“ATG003 (mecamylamine)” NCT00607750 ↗ |
| Known as | Inversine | “Mecamylamine (Inversine ®) is a noncompetitive, high affinity nAChR antagonist with low selectivity for the alpha-7 receptor.” NCT00563797 ↗ |
| Known as | MEC | “the nicotinic antagonist, mecamylamine hydrochloride (MEC), with placebo” PMID 18480694 ↗ Jun 2008 |
| Known as | Mecamilamina | ChEMBL registry synonym — accepted as the source's own label CHEMBL267936 ↗ |
| Known as | mecamylamine HCl | “This is a Phase II randomized, double-masked study comparing the safety and efficacy of ATG003 (mecamylamine HCl) 1.0% and 0.3% ophthalmic solutions to placebo in patients with...” NCT00414206 ↗ |
| Known as | mecamylamine hydrochloride | “the nicotinic antagonist, mecamylamine hydrochloride (MEC), with placebo” PMID 18480694 ↗ Jun 2008 |
| Known as | NSC-757086 | ChEMBL registry synonym — accepted as the source's own label CHEMBL267936 ↗ |
| Action | Inhibit | “the nicotinic receptor antagonist mecamylamine hydrochloride (Inversine)” NCT00319319 ↗ |
| Modality | Small molecule | — CHEMBL267936 ↗ |
| Route | Oral | “mecamylamine 1.25-5 mg PO x 1 dose” NCT00262470 ↗ |